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OBJECTIVES The purpose of the study was to examine the potential renal protective effect of low-dose
dopamine in high-risk patients undergoing coronary angiography.
BACKGROUND Contrast nephropathy is prevalent in patients with chronic renal failure (CRF) and/or
diabetes mellitus (DM). Decreased renal blood flow due to vasoconstriction was suggested as
a contributory mechanism. Low-dose dopamine has a dilatory effect on the renal vasculature.
METHODS Sixty-six patients with mild or moderate CRF and/or DM undergoing coronary angiography
were prospectively double-blindedly randomized, to either 120 ml/day of 0.9% saline plus
dopamine 2 mg/kg/min (Dopamine group) or saline alone (Control group) for 48 h.
RESULTS Thirty-three Dopamine-treated (30 diabetics and 6 with CRF) and 33 Control (28 diabetics
and 5 with CRF) patients were compared. Plasma creatinine (Cr) level increased in the
Control group from 100.6 6 5.2 before to 112.3 6 8.0 mmol/liter within five days after
angiography (p 5 0.003), and in the Dopamine group from 100.3 6 5.4 before to 117.5 6
8.8 mmol/liter after angiography (p 5 0.0001), respectively. There was no significant
difference in the change of Cr level (DCr) between the two groups. However, in a subgroup
of patients with peripheral vascular disease (PVD), DCr was 22.4 6 2.3 in the Control group
and 30.0 6 12.0 mmol/liter in the Dopamine group (p 5 0.01). No significant difference
occurred in DCr between Control and Dopamine in subgroups of patients with preangio-
graphic CRF or DM.
CONCLUSIONS Contrast material caused a small but significant increase in Cr blood level in high-risk
patients. There is no advantage of dopamine over adequate hydration in patients with mild
to moderate renal failure or DM undergoing coronary angiography. Dopamine should be
avoided in patients with PVD exposed to contrast medium. (J Am Coll Cardiol 1999;34:
1682–8) © 1999 by the American College of Cardiology
Impairment of renal function following exposure to radio-
graphic contrast materials is the third major cause of
hospital-acquired renal dysfunction (1). It occurs most often
in patients with chronic renal failure (CRF) (2) and/or
diabetes mellitus (DM) (3–5) and contributes to morbidity
and mortality. Decreased renal blood flow due to vasocon-
striction contributes among other mechanisms to contrast-
associated nephropathy (6). Various prophylactic measures
have been suggested, but to date only appropriate hydration
is generally accepted (7). “Renal-dose” (low-dose) dopamine
has been proposed to prevent contrast nephropathy via a
dilatory effect on the renal vasculature and increased renal
plasma flow and glomerular filtration rate (8), direct effect
on tubular function (9), and increase in cardiac output. We
therefore performed a prospective double-blind randomized
study on the effect of dopamine in high-risk patients
undergoing coronary angiography.
PATIENTS AND METHODS
Patients with chronic renal failure (CRF) and/or diabetes
mellitus (DM) who underwent coronary angiography were
prospectively studied. Included were diabetic patients
treated with insulin or oral hypoglycemic drugs and patients
who had serum creatinine (Cr) concentration exceeding 130
mmol/liter. Excluded were patients with severe renal insuf-
ficiency (serum Cr .200 mmol/liter), acute coronary con-
ditions (myocardial infarction or unstable angina associated
with ST-T changes less then 48 h before the treatment
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protocol), known intolerance to dopamine, allergy to con-
trast material or pheochromocytoma.
Study protocol. All patients received intravenous (IV)
hydration for 8 to 12 h before and 36 to 48 h after
angiography with 0.45% saline/5% dextrose, 100 ml/h or
more according to urine output. In addition, the patients
were randomly assigned to receive through another IV line
either 120 ml/day of 0.9% saline plus dopamine 2 mg/kg/
min (Dopamine group), or saline alone (Control group) for
48 h. The randomization scheme and marked vials with the
solutions were prepared by the hospital pharmacist, leaving
the treating physicians blinded to the treatment. Mannitol
was not given to any of the studied patients.
The radiocontrast agent used in the two groups was
nonionic low-osmolality (Ultravist 370-lopromide
0.769 g/ml, 370 mg lodine/ml, courtesy of Schering).
Diuretics (if signs of congestion ensued) and/or more IV
fluids (if excessive diuresis and dehydration developed) were
permitted at the discretion of the treating cardiologist.
Diabetic patients received 8 U of short-acting insulin with
each 1,000 ml of 0.45% saline/dextrose 5%, and subcutane-
ous insulin as needed according to glucose blood levels.
Urine was collected before angiography, on the first, second,
and fifth days after angiography, and upon discharge. Urine
and blood samples were taken and examined for Cr, urea,
glucose, calcium, phosphate, uric acid, Na1 and K1 levels
upon termination of every urine collection. Radiocontrast
nephropathy was defined as increase in serum Cr concen-
tration of $40% of baseline after the injection of the
radiocontrast agents.
Preangiographic and the highest postangiographic values
of Cr and other biochemical and hematological values
measured on the same day were compared in each group.
The difference between the preangiographic and postangio-
graphic values (D) of each parameter was calculated and
compared between groups. Comparison of the D between
the preangiographic and postangiographic values of each
parameter was also performed between subgroups of pa-
tients with DM, high preangiographic Cr, or previous
radiocontrast nephropathy. Informed consent was given by
all patients, and the protocol was approved by the Institu-
tional Review Board.
Statistical analysis. To assess the differences between the
treatment and the control groups for continuous variables at
study entry, the two-sample t test as well as the nonpara-
metric Mann-Whitney test were applied. The chi-square
test and the Fisher exact test were applied for assessing the
difference between the treatment groups for qualitative
variables. A repeated-measures analysis of variance
(ANOVA) was performed on all biochemical values to
verify group effect, time effect (change in value during the
study based on preangiographic and highest postangio-
graphic measurements) and the interaction between both.
All p values were two-tailed, and statistical significance was
declared if the observed significance level was 5% or less.
RESULTS
Sixty-eight patients entered the study protocol. In one
Dopamine group patient the treatment protocol was
stopped because of pulmonary edema, and in one Control
group patient it was stopped because of cardiogenic shock
and mechanical ventilation. This left 33 patients in the
Dopamine group and 33 in the Control group. Demo-
graphic and clinical data, and basic biochemical and hema-
tological data, were similar in both groups (Table 1).
Patients from both groups were treated with similar drugs,
including angiotensin-converting enzyme inhibitors, diuret-
ics, beta-blockers, calcium channel blockers, hypoglycemics,
nitrates, statins and fibrates.
In the Dopamine group, 23 patients were diabetic, 7 had
both CRF and DM, and 3 had CRF (but not DM) due to
nephrolithiasis or unknown etiology. In the Control group,
21 patients were diabetic, 7 had both CRF and DM, and 5
had CRF (but not DM) due to hypertension, previous
contrast nephropathy, nephrolithiasis or unknown etiology.
The periangiographic complication rate was not different
between the Dopamine and the Control groups: palpita-
tions were reported by four Control and one Dopamine
patient owing to sinus tachycardia or atrial premature beats
(the patient receiving dopamine had sinus tachycardia). In
all of them the protocol was stopped for 1 h and then
renewed within 1 h with no further disturbances or com-
plications. One patient from the Control group died during
hospitalization. This patient underwent coronary artery
bypass grafting (CABG) three years before hospitalization,
and was catheterized because of unstable angina pectoris
and recurrent pulmonary edema. Three days after diagnostic
coronary angiography (which revealed severe triple-vessel
disease and occluded grafts) he had an acute abdominal
pain, the blood pressure fell, and the patient succumbed
despite immediate fluid and cardiopulmonary resuscitation.
Two patients from the Control group and one patient from
the Dopamine group were treated with furosemide.
Six patients (2 Control and 4 Dopamine) developed
radiocontrast nephropathy (defined as increase in Cr level by
.40% of baseline). These patients had a higher Cr level on
admission compared to the remaining patients (p 5 0.003,
Mann-Whitney), and reduced left ventricular function (5 of
6 patients, not statistically significant owing to small num-
Abbreviations and Acronyms
CABG 5 coronary artery bypass grafting
Cr 5 creatinine
CRF 5 chronic renal failure
DM 5 diabetes mellitus
PVD 5 peripheral vascular disease
D 5 the difference between preangiographic and
postangiographic value
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bers). Amount of contrast material and other clinical and
laboratory data in these patients were similar to the rest of
the patients.
Laboratory values before and after angiography. There
were no significant differences between the two groups with
regard to biochemical values including Cr and urea both
before and after angiography, or to hematological values
(Table 2).
Serum Cr levels before and on days 1, 2 and 5 after
angiography were 100.5 6 6.0, 99.6 6 6.8, 102.7 6 6.5 and
117.4 6 10.6 (24 patients) mmol/liter in the Control group,
and 100.2 6 6.3, 102.5 6 7.6, 110.3 6 9.3 and 113.2 6
10.9 (24 patients) mmol/liter in the Dopamine group.
Serum Cr level increased in the Control group from
100.6 6 5.2 before, to the highest postangiographic levels of
112.3 6 8.0 mmol/liter (p 5 0.003), and in the Dopamine
group from 100.3 6 5.4 before, to the highest postangio-
graphic levels of 117.5 6 8.8 mmol/liter (p 5 0.0001).
Table 1. Demographic and Clinical Data
Control
(n 5 33)
Dopamine
(n 5 33)
p
Value
Age (yrs) 59.9 6 1.7 62.9 6 1.2 NS
Female 6/33 (18%) 9/33 (27%) NS
Weight 71.8 6 2.7 75.5 6 2.3 NS
Amount of contrast material used (ml) 163.2 6 13.2 173.8 6 13.0 NS
Urine volume (per day) during study protocol 1979 6 174 2106 6 158 NS
Serum Cr level before angiography (mmol/liter) 100.6 6 5.2 100.3 6 5.4 NS
Chronic renal failure 6/33 (18%) 8/33 (24%) NS
Previous exposure to contrast agents 18/33 (54%) 16/33 (48%) NS
Previous radiocontrast nephropathy 2/33 (6%) 1/33 (3%) NS
Diabetes mellitus (DM) 28 (79%) 30 (91%) NS
Diabetic nephropathy: Proteinuria 9/24 (37.5%) 13/20 (65%) NS
History of hypertension 14/33 (42%) 22/33 (67%) NS
Systolic BP on admission 131.4 6 3.9 141.5 6 4.9 NS
Diastolic BP on admission 75.7 6 1.7 79.1 6 2.7 NS
Hyperlipidemia 16/33 (48%) 16/33 (48%) NS
Smoking 14/33 (42.4%) 14/33 (42.4%) NS
Ischemic heart disease 30/33 (90%) 30/33 (90%) NS
Congestive heart failure 9/33 (27%) 12/33 (36%) NS
Moderate-poor left ventricular function 17/26 (65%) 13/26 (50%) NS
Peripheral vascular disease 7/33 (21%) 11/33 (33%) NS
Table 2. Biochemical Values Before and After Catheterization
Control
(n 5 33)
Dopamine
(n 5 33)
p
Value
Before Catheterization
Na (mmol/liter) 138.03 6 0.49 137.51 6 0.66 NS
K (mmol/liter) 4.16 6 0.09 4.08 6 0.09 NS
Urea (mmol/liter) 7.29 6 0.54 6.85 6 0.53 NS
Creatinine (mmol/liter) 100.57 6 5.19 100.27 6 5.41 NS
Uric acid (mmol/liter) 380.59 6 28.66 376.45 6 33.38 NS
Glucose (mmol/liter) 10.41 6 1.15 10.00 6 1.05 NS
Hemoglobin (g%) 13.24 6 0.29 13.50 6 0.27 NS
Hematocrit (%) 39.48 6 0.89 39.94 6 0.78 NS
After Catheterization
Na (mmol/liter) 138.75 6 0.58 138.75 6 0.59 NS
K (mmol/liter) 4.27 6 0.10 4.27 6 0.07 NS
Urea (mmol/liter) 7.92 6 0.82 7.55 6 0.61 NS
Creatinine (mmol/liter) 112.27 6 8.00 117.54 6 8.80 NS
Uric acid (mmol/liter) 338.88 6 20.32 401.56 6 31.11 NS
Glucose (mmol/liter) 11.98 6 1.09 12.13 6 0.90 NS
Hemoglobin (g%) 12.9 6 0.28 13.03 6 0.28 NS
Hematocrit (%) 38.57 6 0.89 38.62 6 0.80 NS
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There was no difference in DCr between the two groups
(11.7 6 4.9 and 19.2 6 6.0, respectively, p 5 NS) (Fig. 1).
These results were confirmed in the repeated-measures
ANOVA (Table 3). There was a significant “within group
(time)” effect for Cr, urea, hemoglobin and hematocrit, and
K, but no significant “between groups” or “interaction
(GrouppTime)” effect (Table 3).
In a subgroup of patients with peripheral vascular disease
(PVD) (7 Control and 11 Dopamine patients), however,
DCr was 22.4 6 2.3 and 30.0 6 12.0 mmol/liter in the
Control and Dopamine groups, respectively (p , 0.05) (Fig.
2). There was no difference in other parameters between the
patients with and without PVD. There was no significant
difference in DCr or D of other examined parameters in
another subgroup of patients (6 Control and 5 Dopamine)
with high Cr (.110 mmol/liter) or high urea (.10 mmol/
liter) before angiography. Neither was there a difference
between Control and Dopamine patients in the subgroups
of diabetic patients and patients with previous contrast
nephropathy.
Urea levels increased in the Control and Dopamine
groups from 7.3 6 0.5 before to 7.9 6 0.8 mmol/liter after
angiography (p 5 NS), and from 6.8 6 0.5 before to 7.5 6
0.6 mmol/liter after angiography (p 5 0.05), respectively.
D-urea was not statistically different between the two
groups. There was no difference in the D of other biochem-
ical values between the two groups (Table 4).
Of the 66 patients enrolled in the study, 14 patients
(7 Dopamine and 7 Control) had both DM and Cr .110
mmol/liter before angiography. Creatinine level in these
14 patients was 134.4 6 4.9 mmol/liter compared to 91.3 6
3.3 mmol/liter in the other 52 patients (who had either CRF
or DM but not both; p , 0.0001) before angiography, and
it was 155.6 6 10.1 and 103.9 6 5.9 mmol/liter in the 14
and 52 patients, respectively (p 5 0.0002), after angiogra-
phy. The DCr was 21.3 6 10.8 and 12.6 6 3.4 mmol/liter
in the 14 and 52 patients, respectively, p 5 0.45 (NS). The
14 diabetic–CRF patients did not differ from the 52 patients
in other clinical and biochemical parameters or in the
amount of contrast medium used during the procedure.
Urea level was 9.9 6 1.0 and 6.3 6 0.3 mmol/liter in the
14 and 52 patients, respectively (p 5 0.003), before angiog-
raphy, and it was 10.8 6 1.1 and 6.9 6 0.5 mmol/liter in the
14 and 52 patients, respectively (p 5 0.001), after angiog-
raphy. The Durea was 0.9 6 0.7 and 0.6 6 0.3 mmol/liter
in the 14 and 52 patients, respectively (p 5 NS). There were
no differences between the seven diabetic–CRF patients
from the Dopamine group and the seven diabetic–CRF
patients from the Control group in the Cr and urea levels
before and after angiography, and in DCr and Durea.
Figure 1. DCr (1, before; 2, after angiography) in the Control and
Dopamine groups were similar (11.7 6 4.9 and 19.2 6 6.0,
respectively, p 5 NS).
Table 3. Two-Way Repeated-Measures ANOVA for the
Biochemical Parameters
Between-
Groups
Effect
Within-Groups
(Time)
Effect
Interaction
(Group 3
Time) Effect
Na p 5 0.6166 p 5 0.0934 p 5 0.7231
K p 5 0.8297 p 5 0.0410 p 5 0.5069
Urea p 5 0.6332 p 5 0.0338 p 5 0.9140
Creatinine p 5 0.7900 p 5 0.0001 p 5 0.4325
Uric acid p 5 0.3880 p 5 0.1440 p 5 0.6092
Glucose p 5 0.8704 p 5 0.0103 p 5 0.4688
Hemoglobin p 5 0.6288 p 5 0.0054 p 5 0.6039
Hematocrit p 5 0.8665 p 5 0.0053 p 5 0.6081
Figure 2. In patients with peripheral vascular disease, DCr (1,
before; 2, after angiography) was 22.4 6 2.3 mmol/liter in the
Control group and 30.0 6 12.0 mmol/liter in the Dopamine
group, p , 0.05.
Table 4. The Change (D) in Biochemical Values Before and
After Catheterization
Control
(n 5 33)
Dopamine
(n 5 33)
p
Value
Na (mmol/liter) 0.71 6 0.59 1.09 6 0.89 NS
K (mmol/liter) 0.11 6 0.11 0.21 6 0.10 NS
Urea (mmol/liter) 0.63 6 0.51 0.70 6 0.34 NS
Creatinine
(mmol/liter)
11.69 6 4.94 19.27 6 6.04 NS
Uric acid
(mmol/liter)
220.12 6 15.93 210.00 6 12.02 NS
Glucose
(mmol/liter)
1.57 6 1.28 2.79 6 1.08 NS
Hemoglobin (g%) 20.34 6 0.20 20.49 6 0.21 NS
Hematocrit (%) 20.97 6 0.62 21.39 6 0.54 NS
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DISCUSSION
The reported incidence of contrast nephropathy ranges from
none to more than 50% (2,10,11), depending on whether
the study was retrospective or prospective and on the
presence or absence of risk factors or their combination (12).
Preexisting renal insufficiency and DM are the most prev-
alent risk factors (12,13).
Mechanisms of contrast nephropathy. The mechanism of
contrast nephrotoxicity is multifactorial. Contrast material
stimulates the renin-angiotensin system (14) and blocks
renal prostaglandin (15) with subsequent vasoconstriction
and reduction in renal blood flow and glomerular filtration
rate. Patients with diabetic nephropathy and CRF are at a
higher risk owing to an increased vasoconstrictor state, both
hormonal and structural (16). The addition of ischemic
insult to an already damaged kidney may induce irreversible
cell injury (17). Additional mechanisms include increased
intrarenal pressure (18), a role for calcium (19), a change in
red blood cells morphology (20), and shunting of blood flow
from the renal cortex to the renal medulla (21). Other
proposed mechanisms include altered glomerular perme-
ability and selectivity, direct cell toxicity, tubule obstruction
with proteinaceous casts or uric acid or oxalate crystals (22),
immunologic injury (23), and medullary hypoxia causing
injury to the thick ascending limb cells (24).
Prevention of contrast nephropathy is of a major interest.
Patient selection is the most important imperative. In a
nonrandomized study hydration dramatically reduced con-
trast nephropathy (7), and this may explain the decrease in
incidence of contrast nephropathy in recent prospective
studies. Prophylactic treatment with mannitol or furo-
semide was recommended by some investigators (25) and
disproved in subsequent studies (26,27). Theophylline, a
nonspecific adenosine receptor antagonist, has been sug-
gested recently for prevention of contrast nephropathy (28).
Dopamine and contrast nephropathy in high-risk pa-
tients. Dopaminergic receptors of two distinct subtypes
(DA1, DA2) are localized in different parts of the kidney.
The hemodynamic actions of dopamine are dose-
dependent. In low doses (0.5 to 2.5 mg/kg/min) dopamine
stimulates dopaminergic receptors in the renal and mesen-
teric vasculature, resulting in selective vasodilation. Inter-
mediate doses (2 to 5 mg/kg/min) favor beta-adrenergic
stimulation, and at the highest doses (.5 mg/kg/min)
alpha-adrenergic actions appear. Low dose (“renal dose”) of
dopamine increases renal plasma flow, glomerular filtration
rate (GFR), and sodium excretion in subjects with normal
renal function and with congestive heart failure (8,29,30)
and may increase urine output in patients with acute oliguric
renal failure who do not respond to furosemide (31).
Other mechanisms by which dopamine exerts its renal
effects include an increase in cardiac output and a global
increase in perfusion through stimulation of beta-adrenergic
receptors, increased delivery of diuretics to the distal tubule,
decrease in serum aldosterone concentrations, and direct
effect on tubular function (9). Seriously ill patients who
commonly decrease their renal function with a fall in urine
output have been treated with dopamine in intensive care
units (9,29). Although to date no controlled study has
shown an improved clinical outcome to support this prac-
tice, treatment with low-dose dopamine has become routine
in many units. Goligorski et al. (32) questioned 50 promi-
nent nephrologists on their preferences and approaches in a
patient with ATN (acute tubular necrosis). Of 36 who
responded, 33% answered they would use renal-dose dopa-
mine, 48% would use both renal-dose dopamine and loop
diuretics, and 33% would add calcium channel blockers.
The investigators concluded that although “today’s thera-
peutic management of ATN is an art, rather than a science
of medicine,” their survey provides consensus therapeutic
guidelines. This practice has extended to the postcoronary
bypass and aneurysm repair patient in the intensive care unit
setting, often extending the stay and increasing the cost of
care with little evidence of patient benefit (33).
Many patients who undergo coronary angiography have
CRF and/or DM. This large population could benefit from
a renal protective effect. Because exposure to contrast
material may result in prolonged vasoconstriction and a
decline in the renal blood flow, administration of dopamine
in a low dose was suggested to induce vasodilation and
preserve renal function, and was examined in a few small
series of patients undergoing diagnostic peripheral or vis-
ceral angiography. A preliminary study by Hall et al. (34)
suggested such a protective effect. The study was prospective
but not randomized and not blinded, and the patients were
treated with dopamine and fluids for less than 24 h.
Statistically significant difference was reached only in a
subgroup of 11 patients with baseline Cr $177 mmol/liter
who received dopamine. Hans et al. (35) found that dopa-
mine administration during and 12 h after angiography
induced a small improvement in Cr clearance compared to
controls, but this was not sustained after day 1. In another
study, low-dose dopamine did not prevent radiocontrast
nephropathy in 15 patients compared to controls (5);
dopamine, however, was given for only 2 h after catheter-
ization, and all patients had Cr levels $1.8 mmol/liter.
In a previous study, intermediate-dose dopamine (5
mg/kg/min) given to diabetic patients for 6 h after coronary
angiography suggested a protective effect from contrast
nephropathy (36). Biochemical follow-up in that study was
short (24 h routinely, and 72 h only when necessary). In the
present study we used low-dose dopamine for 36 to 48 h
after angiography, a longer period than in previous studies
(2 to 24 h). All patients were followed for 48 h after the
procedure, and 24 patients in each group were followed for
five days. The average amount of contrast material used was
170 cc, higher than the amount (100 to 120 ml) used in
previous studies, because many of our patients underwent
both angiography and angioplasty at the same session.
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Meticulous fluid balance was maintained, and similar urine
volumes were measured in the two groups.
We found that contrast material caused a small but
significant increase in Cr blood level in both Control and
Dopamine groups. This small increase in Cr is similar to
that found in other studies when patients were properly
hydrated before and after injection of contrast material. The
increase in Cr usually started on the second day after
angiography and persisted until the fifth day. A comparison
of the two groups showed that dopamine did not offer a
significant protective renal effect, nor did it have a delete-
rious effect in the groups and in most subgroups studied. A
subgroup of 14 especially high-risk patients who had both
CRF and DM had significantly higher Cr and urea levels
before angiography compared to the other 52 patients who
had either CRF or DM. Creatinine and urea levels in-
creased similarly after angiography in the 14 and 52 pa-
tients. Dopamine had neither protective nor deleterious
effect in the subgroup of patients with both CRF and DM.
Interestingly, uric acid blood level decreased in the Control
group and increased in the Dopamine group (statistically
insignificant). A similar finding of 6-hydroxydopamine-
induced increase in brain tissue uric acid has been reported
in the guinea pig (37). The reason for the change in uric acid
in our study is not known, but tubular effect of dopamine
cannot be excluded.
Effect of dopamine in patients with PVD. In a subgroup
of patients with PVD (diagnosed by symptoms of intermit-
tent claudication and noninvasive or invasive vascular inves-
tigations), the change in Cr level was significantly greater in
dopamine-treated patients compared to the Control group.
The reason for the deleterious effect of dopamine in PVD
patients is not known. To our knowledge, the use of
renal-dose dopamine has not previously been demonstrated
to be clearly damaging in patients with PVD.
Reported dopamine complications include cardiac ar-
rhythmias, myocardial ischemia and infarction, blunted
hypoxic ventilatory drive, increased pulmonary shunt frac-
tion in critically ill patients, digital necrosis (6,10,38), and
possibly intestinal mucosal ischemia leading to translocation
of bacterial products (12,39). In our study, the protocol
treatment was well tolerated. The complication rate was
similar or somewhat higher in the Control group and
cannot be attributed to the dopamine. Moreover, although
this report deals exclusively with patients undergoing coro-
nary angiography, the general massage is applicable to any
diabetic or mild renal failure patient receiving contrast
medium.
In summary, contrast material caused a small but signif-
icant rise in serum Cr level in patients undergoing coronary
angiography. Our findings do not support a renal protective
role of dopamine for high-risk patients exposed to contrast
material. Patients resistant to diuretic therapy (e.g., with
heart failure) may be treated with low-dose dopamine if
necessary in conjunction with watchful hydration. Low-
dose dopamine infusions for renal prophylaxis should be
avoided in patients with PVD until larger series of these
patients are examined.
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